Biosensors Integration in blood-brain barrier-on-a-chip: emerging platform for monitoring neurodegenerative diseases

Fecha de publicación

2024-07-04T16:20:12Z

2024-07-04T16:20:12Z

2022-05-13

2024-07-04T16:20:17Z

Resumen

Over the most recent decades, the development of new biological platforms to study disease progression and drug efficacy has been of great interest due to the high increase in the rate of neurodegenerative diseases (NDDs). Therefore, blood–brain barrier (BBB) as an organ-on-a-chip (OoC) platform to mimic brain-barrier performance could offer a deeper understanding of NDDs as well as a very valuable tool for drug permeability testing for new treatments. A very attractive improvement of BBB-oC technology is the integration of detection systems to provide continuous monitoring of biomarkers in real time and a fully automated analysis of drug permeably, rendering more efficient platforms for commercialization. In this Perspective, an overview of the main BBB-oC configurations is introduced and a critical vision of the BBB-oC platforms integrating electronic read out systems is detailed, indicating the strengths and weaknesses of current devices, proposing the great potential for biosensors integration in BBB-oC. In this direction, we name potential biomarkers to monitor the evolution of NDDs related to the BBB and/or drug cytotoxicity using biosensor technology in BBB-oC.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

American Chemical Society

Documentos relacionados

Reproducció del document publicat a: https://doi.org/10.1021/acssensors.2c00333

ACS Sensors, 2022, vol. 7, num.5, p. 1237-1247

https://doi.org/10.1021/acssensors.2c00333

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

cc-by (c) Mir, Mònica, et al., 2022

http://creativecommons.org/licenses/by/3.0/es/

Este ítem aparece en la(s) siguiente(s) colección(ones)